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Objective: We aimed to examine the 30-day unplanned readmissions rate, predictors of readmission, causes of readmissions and clinical impact of readmissions after PCI.
Background: Unplanned rehospitalizations following percutaneous coronary intervention (PCI) carry significant burden to both patients and to the local healthcare economy, and are increasingly considered as an indicator of quality of care. 
Methods: Patients undergoing PCI between 2013 and 2014 in the US Nationwide Readmission Database were included. Incidence, predictors, causes and cost of 30-day unplanned readmissions were determined. 
Results: A total of 824,747 patients with PCI were included, of whom 77,178 (9.3%) had an unplanned readmission within 30 days. Length of stay for the index PCI was greater (4.7 vs 3.9 days) and mean total hospital cost ($23,880 vs $37,524) was higher for patients who were readmitted compared with those not readmitted. The factors strongly independently associated with readmissions were index hospitalization discharge against medical advice (OR 1.91, 1.65-2.22), transfer to short-term hospital for inpatient care (OR 1.62,1.38-1.90), discharge to care home (OR 1.57, 1.51-1.64) and chronic kidney disease (OR 1.50, 1.44-1.55). Charlson comorbidity score and number of comorbidities were independently associated with unplanned readmission (OR 1.26, 1.25-1.28 and 1.17, 1.16-1.18).  The majority of readmissions were due to non-cardiac causes (56.1%). 
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PCI = percutaneous coronary intervention
USA = United States of America
UK = United Kingdom
AHRQ = Agency for Healthcare Research and Quality
CABG = coronary artery bypass graft
TIA = transient ischemic attack
CCS = Clinical Classification Software
ICD = International Classification of Diseases




Unplanned rehospitalizations following percutaneous coronary intervention (PCI) carry significant burden to both patients and to the local healthcare economy, and are increasingly considered as an indicator of quality of care. 
Our analysis of 825,747 PCI procedures demonstrates that unplanned readmissions within 30 days of the index PCI are common.  Most readmissions are were due to non-cardiac causes (56.1%) and comorbidities and discharge location are strong predictors of unplanned 30-day readmission.




Percutaneous coronary intervention (PCI) is the most common revascularization modality for the treatment of coronary disease, accounting for 3.6% of all invasive procedures in the USA in 2011.1 As the mean in-hospital mortality after PCI is less than 1%,2 readmissions after PCI are increasingly recognized as an important post-discharge outcome.  In addition, rate of readmission increasingly used as a quality of care indicator at the institutional level, in addition to being an important burden to patients and the local healthcare economy.3
The nature and impact of readmissions is complex. Despite efforts to reduce early readmissions, readmissions rates after PCI have been reported to be between 4.7% and 15.6%.3 Hospital readmissions may act as a surrogate of the quality of care received from the initial hospitalization,4 as they may result from actions taken or omitted during the initial hospital stay,5 or they may be a consequence of incomplete treatment or failure of services to coordinate post-discharge care.6,7 Unplanned readmissions can also be considered an adverse outcome for patients. From the health service perspective, the financial impact of readmissions is significant, with a readmission within 30-days associated with financial penalties.8 Furthermore, in the USA, the Affordable Care Act includes financial penalties for hospitals that have risk adjusted readmissions rates for specific conditions exceeding specific benchmarks9 whilst in the UK, hospitals do not receive any additional payments for treatment if patients are readmitted within 30 days.10




Participants and study design
The NRD provides a nationally representative sample of all-age, all-payer discharges from US non-federal hospitals produced by the Healthcare Cost and Utilization Project of the Agency for Healthcare Research and Quality.11 This database is constructed from the discharge-level data of hospitalizations from 21 geographically-dispersed participating states which represents 49.3% of the total US population and 49.1% of all US hospitalizations.12 Readmissions are determined through the de-identified unique patient linkage number assigned to each patient, which allows tracking of patients across hospitals within a state during a calendar year.
Individual patients in the NRD dataset are assigned up to 15 procedure codes for each admission to hospital.  We defined patients with PCI with procedure code 0066 (PTCA OR CORONARY ATHER), 3606 (INSERT CORON ART STENT) and 3607 (INSERT DRUGELUTING CRNRY AR). Only patients who were discharged alive after PCI were considered in the analysis.  Planned readmissions were excluded which were defined by readmissions within 30 days which were classified as elective.
 
Outcomes and measurements
The primary outcome was the rate of unplanned readmission within 30 days of hospitalization with PCI.  We included patients who underwent PCI with discharge dates in 2013 and 2014 with 30-day follow up.  We excluded patient admitted in December of both calendar years because they would have not 30-day follow up and patients who had planned readmissions.  Total cost of (i) index admission and (ii) readmissions (where relevant) for each patient was determined by multiplying the hospital charges with AHRQ’s all-payer cost-to-charge ratios for each hospital. 
We used ICD-9 codes to define clinical variables including smoking status, dyslipidemia, coronary artery disease, previous myocardial infarction, previous PCI, previous CABG, previous stroke or TIA, atrial fibrillation, dementia and receipt of circulatory support. The other comorbidity variables in the analysis were available via the Elixhauser comorbidities13 which included alcohol misuse, chronic lung disease, heart failure, diabetes, valvular heart disease, peptic ulcer disease, hypertension, renal failure, obesity, cancer, fluid and electrolyte disorders, depression, peripheral vascular disease, hypothyroidism, liver disease, anemia and coagulopathy. The paralysis variable from the Elixhauser comorbidities was used as a surrogate for hemiplegia, and connective tissue disease and leukemia where defined by CCS codes 210, 211 & 39 respectively. Combining these variables enabled us to compute the Charlson comorbidity index.  The number of comorbidities was the sum of the comorbidities included in the analysis.  Procedural ICD-9 codes were used to define multivessel disease, bifurcation disease, circulatory support, vasopressor use, intra-aortic balloon pump use, fractional flow reserve use, intravascular ultrasound and drug eluting stent use.  Diagnostic ICD-9 codes were used to define in-hospital outcomes including complete heart block, transient ischaemia attack or stroke, cardiogenic shock, cardiac arrest, acute kidney injury, major bleeding, blood transfusion, vascular complication and emergency CABG.  Additional data were collected on length of stay in hospital, hospital bed size, hospital location and hospital teaching status and discharge destination. The causes of readmission were determined by the first diagnosis based on Clinical Classification Software codes which are presented in detail in Supplementary Table 1.
Statistical analysis




	A total of 853,955 patients underwent PCI between 2013 to 2014.  After exclusion of 21,103 patients who died during the index admission (2.5%) and another 8,105 patients who had planned PCI readmission within 30 days, 824,747 patients with PCI procedures were included in the analysis.  At 30 days, 77,178 (9.3%) participants had an unplanned readmission.
	The baseline characteristics of the participants during their initial hospital episode are shown in Table 1. Participants who were readmitted were more likely to be older (67.3 vs 64.7 years), female (39.4% vs 31.6%) and admitted on the weekend (22.8% vs 22.3%). Significant differences were also observed depending on the primary expected payer and median household income where private healthcare (29.8% vs 18.2%) and higher median household income (highest quartile 21.3% vs 19.6%) was associated with reduced rates of readmissions.
	Multi-morbidity was also more prevalent amongst patients who were readmitted within 30 days. Specifically, the mean number of comorbidities was 5.7 in the readmitted group compared to 4.9 in the no readmission group, with a higher Charlson Comorbidity score in the readmitted group (1.9 vs 1.3, p<0.001). Significant differences were observed in treating hospital characteristics, with differences observed based on bed size of the hospital and teaching status but not based on location.  Significant differences were recorded for in-hospital complete heart block (1.4% vs 1.2%), TIA/stroke (3.7% vs 3.2%), acute kidney injury (1.0% vs 0.8%), major bleeding (1.1% vs 0.8%), blood transfusion (0.11% vs 0.05%) and vascular complications (1.0% vs 0.8%), that were all more frequent in the readmission group.  
For the first admission for PCI, length of stay was greater in patients who were readmitted (4.7 vs 3.9 days) and they were more likely to be transferred to another institution (8.9% vs 4.6%) or go to a care home on discharge (14.1% vs 7.0%). The mean cost for the index PCI and total cost for index and first readmission were $23,880±21,476, $37,524±25,679 respectively (Figure 1).
	The independent predictors of 30-day readmission are shown in Table 2.  Factors around discharge and discharge destination were most associated with unplanned readmission. Patients self-discharging against medical advice (OR 1.91, 1.65-2.22, p<0.001), short term hospital (OR 1.62, 1.38-1.90, p<0.001), care home (OR 1.57, 1.51-1.64, p<0.001) and transfer to other institution (OR 1.41, 1.32-1.50, p<0.001) were independently associated with unplanned readmission within 30 days.  Comorbidities were also associated with readmission, with the largest odds ratios observed in chronic kidney disease (OR 1.50, 1.44-1.55, p<0.001), liver disease (OR 1.42, 1.30-1.55), atrial fibrillation (OR 1.41, 1.36-1.46, p<0.001) and chronic lung disease (OR 1.36, 1.31-1.40, p<0.001). Participants who had private insurance (OR 0.67, 0.64-0.70, p<0.001), no insurance (OR 0.69, 0.64-0.74, p<0.001), elective index admission (OR 0.70, 0.66-0.74, p<0.001) and drug eluting stent (OR 0.82, 0.80-0.85, p<0.001) were independently associated with a decreased risk of unplanned 30-day readmission. Comorbidity burden as defined by Charlson comorbidity index (OR 1.26 95%CI 1.25-1.28, p<0.001) or number of comorbidities (OR 1.17, 1.16-1.18, p<0.001) was independently associated with readmission.
	The causes of readmission are shown in Figure 2.  The readmissions due to non-cardiac causes were slightly more common (56.1%). Among the non-cardiac causes for readmission the most common causes were non-specific chest pain (14.8%), infection (12.3%), gastrointestinal disease (10.4%), respiratory disease (8.6%) and major bleeding complications (5.9%).  Among cardiac causes for readmission the most common causes were coronary artery disease including angina (31.6%), heart failure (25.1%), acute myocardial infarction (21.6%), arrhythmias (15.8%) and pericarditis (1.5%).
	Table 3 shows the predictors of non-cardiac and cardiac readmissions after PCI.  Factors with significant associations only for non-cardiac readmissions were hypertension, dementia and vascular complications. Factors with significant associations only for cardiac readmission were smoking, urban location and an index hospitalization occurrence of complete heart block and stroke/transient ischemic attack.
	Figure 3 shows a flow diagram in-hospital mortality for index procedure, cardiac and non-cardiac causes of unplanned readmission. The in-hospital mortality rate for patients undergoing index PCI was 2.5% whilst the in-hospital death among those who had an unplanned readmission was 3.1% for non-cardiac readmissions and 2.8% for cardiac readmissions.

Discussion
	Our analysis of 825,747 PCI procedures demonstrates that unplanned readmissions within 30 days of the index PCI are common (9.3%). The majority of readmissions within 30-days are non-cardiac (56%), with female sex, chronic kidney disease, liver failure, atrial fibrillation, increasing comorbidity burden and discharge location were amongst the strongest predictors of unplanned 30-day readmission. Patients who experienced an unplanned readmission for non-cardiac reasons tended to be younger with more comorbidities including alcohol misuse, cancer and dementia whilst patients who are readmitted for cardiac reasons are more likely to have in-hospital complications at their index PCI event.  Finally, unplanned readmissions were associated with increased mortality rates and healthcare costs.
	Our study overcomes several limitations in the existing literature on unplanned readmissions following PCI.  The largest study of readmissions after PCI currently published described a cohort of Medicare patients between 2000 to 2012 and reported a 30-day readmission rate of 15.8%.14 One of the most important limitations of this study was that it did not distinguish between unplanned and planned readmissions, which may explain why their reported readmission rate was higher compared to the current study in which planned readmissions were excluded. Furthermore, a planned admission for a staged procedure / investigation has neither the healthcare cost implications, nor the impact on hospital services that an unplanned readmission will have. Secondly, the study was undertaken in a Medicare cohort, which limits generalizability to all admissions, in contrast to our study which included Medicaid, private and uninsured patients, as well as Medicare patients.  We observed in the current study that the Medicare cohort had the highest proportion of patients with readmission 63.6% vs 51.8%.  This suggests that a study including only Medicare patients would be a higher risk cohort for unplanned readmission that may not be representative of the wider PCI practice within the United States. Thirdly, the study focused on PCI outcomes from procedures undertaken over 15 years ago and therefore may not represent contemporary practice and its associated outcomes. Other studies have also evaluated readmissions after PCI but are limited because they are small studies derived from either single, or a small number of centres15-18 or are derived from procedures undertaken over ten years ago which may not be relevant to modern PCI practices.19-20
	While our previous work has shown that comorbidity burden has important prognostic impact in PCI,22,23 we find for the first time the comorbidity as defined by the Charlson score and number of comorbidities16,21 are an important predictive tool for unplanned readmissions.  It is not clear whether measures such as greater emphasis on management of comorbid conditions during the index procedure may reduce readmissions or whether comorbidity burden is a surrogate for a higher risk cohort.  An area for future research may be determining if better management of comorbid illness and closer follow up once discharged may reduce unplanned readmissions.

	We found that non-cardiac causes are more common, which may reflect the worsening comorbid burden in patients who undergo PCI overtime. Furthermore, PCI practices have evolved, with improved drug eluting stent designs with thinner struts which reduce stent thrombosis24,25 and powerful antiplatelet agents which reduce major adverse cardiovascular events26,27 and stent thrombosis.27,28 Newer tools, such as fractional flow reserve, help characterize lesions that require treatment and use of intravascular imaging modalities such as IVUS and OCT optimize stent deployment, which has also been shown to improve patient outcomes.29,30 These changes in PCI practices may serve to reduce cardiac causes of readmission. 
Another potential reason for the dominance of non-cardiac readmissions may relate to the decline in length of stay, which may impact on the management / optimization of non-cardiac related comorbidities since improvements in PCI practices facilitate early discharge to reduce associated hospital expenditure. Whilst our analysis suggests that the majority of 30-day unplanned readmissions are non-cardiac in origin, it is important to note that they may still relate or occur as a consequence of the index PCI procedure. For example, patients post PCI are advised to seek medical attention if they experience chest pain, which may explain the increased rates of non-cardiac chest pain reported in our analyses. Other causes of readmission such as bleeding complications may directly relate to the PCI procedure as potent antiplatelet agents prescribed increased the propensity towards such bleeding complications, even if such bleeding events are classified as non-cardiac causes of readmission.
Our results support our previous systematic review that identified that female sex, pre-or periprocedural myocardial infarction, peripheral vascular disease, diabetes, renal failure and non-elective PCI were associated with more readmissions, although data were mostly derived from single centers with small sample sizes and often in less contemporary cohorts.3 Other studies have also identified other predictors that were not evaluated in the current study.  For example, Hannan et al reported reduced ejection fraction, ≥3 number of disease vessels and malignant ventricular arrhythmias as a predictor of readmission.20  Harjai et al also found PCI to LAD, lesion length >28 mm, aspirin dose and PPI use where predictive of readmission.18 Factors that predispose to readmission after PCI will most probably depend on the risk profile of the cohort and the case mix, such as proportion of cases that were elective or emergency. While additional studies16,17,31 have looked at predictors this is the largest study to date, and is the first to study characteristics, predictors and outcomes in a national cohort.
While readmissions are important from a financial perspective, it may not be the ideal quality of care indicator.  The Quality of Care and Outcomes Research in Cardiovascular Disease and Stroke Working group described principles of selection of performance measures32 but readmissions meet some but not all criteria with concerns raised by a previous editorial on readmissions after TAVR implantation.33 Firstly, unplanned readmissions are meaningful as they are a healthcare expenditure and burden to patients.  Secondly, measurements of unplanned readmissions are easily documented, reliable in hospital databases and can be used to compare different healthcare providers.  However, it is unclear that adjustment for patient variability will enable performance of healthcare system to have direct impact on unplanned readmission rates.  Furthermore, it is uncertain if unplanned readmissions can be modified by improvements in processes of care.  There are many studies that have tested interventions aimed to reduce readmissions34 but there are currently no measures with good evidence base that have been shown to reduced readmission after PCI.  
	The prevention of 30-day hospital readmissions has been previously reviewed by Leppin et al.34 While none of the studies in the review were in PCI settings, their reviewed classified different discharge interventions such as a comprehensive discharge planning and home follow-up protocol for elderly which has been shown to reduce readmissions and health expenditures.35 Other interventions have been tested such as telephone follow-up,36 telemonitoring,37 and self-management focused education programs.38  The only study of PCI patients tested an intervention which involved initial patient readmission risk assessment and used a discharge checklist to ensure access to appropriate medications and close follow-up of high risk patients which resulted in a reduction of 30 day readmissions after PCI from 9.6% to 5.3%.39 Targeting specific causes of readmission may be an important area for future research.  For example, specific care paths for recognized causes of readmission after PCI in the emergency room could preclude admission or direct patients for observation rather than in-patient status.  Education for appropriate assessment and management of cardiac/procedure-related complication might also have a role in reducing readmissions.
	Our study has several strengths.  First, this is a large contemporary nationwide cohort which provides results that are generalizable to current PCI practices. The data is nearly complete with no missing data and previous studies using the National Readmission Database only having published data derived from 1 year.40 In addition, we could explore difference in predictors of all unplanned readmissions as well as non-cardiac and cardiac readmissions and further consider explore mortality and length of stay outcomes for patients for both the index and readmission according to causes.
Our study is also subject to the common limitations of retrospective analyses of administrative data. Our data was collected from administrative claims sampled from 21 states, which account for 49% of the US population and hospitalizations but the results of the current study may not be generalizable to all regions as geographic heterogeneity in outcomes could not be explored.41  Secondly, while we were able to review data over a 2-year period, the overall data is comprised of 2 unique datasets corresponding to each in the period 2013 and 2014 and no linkage is possible between years. Third, even though we were able to adjust for a variety of variables and comorbidities, there is still the risk of residual confounding as the study is observational in nature, and the NRD dataset does not capture measures of frailty that are known to impact on PCI outcomes.42  Finally, causes of readmission were identified using the primary discharge diagnosis codes, which may be subject to reporting biases, although previous studies have used a similar approach for TAVR readmissions.43,44
	In conclusion, our results suggest that 30-day readmissions in the United States is common and comorbid illnesses and places of discharge are important factors which influence readmissions.  Clinicians should focus on the optimization of the management of any co-morbid condition during a patient's index admission for PCI and consider developing outreach programs to patients discharged to short term hospitals, other institutions and care homes. There are important financial consequences of such readmissions and further strategies to reduce the prevalence should be explored.
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Table 1: Baseline characteristics and in-hospital outcomes from index admission for PCI patients according to 30-day readmission status





















































































Transfer to other institution	4.6%	8.9%	
Care home	7.0%	14.1%	
Left against medical advice or discontinue care	0.4%	0.8%	
Court or law enforcement	2.7%	0%	
Destination unknown	0.02%	0.02%	






Primary expected payer compared to MedicareMedicaidPrivateUninsuredNo chargeOther	1.11 (1.05-1.17)0.67 (0.64-0.70)0.69 (0.64-0.74)0.89 (0.79-1.02)0.80 (0.74-0.88)	<0.001<0.001<0.0010.087<0.001










Peripheral vascular disease	1.17 (1.13-1.22)	<0.001
Chronic lung disease	1.36 (1.31-1.40)	<0.001
Chronic kidney disease	1.50 (1.44-1.55)	<0.001
Liver disease 	1.42 (1.30-1.55)	<0.001






Fractional flow reserve	1.16 (1.07-1.25)	0.001
Drug eluting stent	0.82 (0.80-0.85)	<0.001
In-hospital TIA/stroke	0.92 (0.86-0.98)	0.013
In-hospital emergency CABG	0.85 (0.75-0.96)	0.009
Length of stay (per 1 day increment)	0.98 (0.98-0.98)	<0.001
Discharge destinationShort term hospital vs home Transfer to other institution vs homeCare home vs homeLeft against medical advice or discontinue care vs home	1.62 (1.38-1.90)1.41 (1.32-1.50)1.57 (1.51-1.64)1.91 (1.65-2.22)	<0.001<0.001<0.001<0.001
Charlson score	1.26 (1.25-1.28)	<0.001





Table 3: Independent predictors of 30-Day non-cardiac, cardiac and PCI-related readmission after PCI

Predictors	Non-cardiac	Cardiac
	OR (95% CI)	P-value	OR (95% CI)	P-value
Age (per 1 year increment)	0.99 (0.99-1.00)	0.002	1.00 (0.99-1.00)	0.16
Female	1.23 (1.19-1.27)	<0.001	1.15 (1.10-1.20)	<0.001
Elective	0.79 (0.74-0.83)	<0.001	0.59 (0.55-0.64)	<0.001
Primary expected payer compared to MedicareMedicaidPrivateUninsuredNo chargeOther	1.06 (0.99-1.14)0.61 (0.58-0.65)0.63 (0.57-0.69)0.79 (0.66-0.93)0.73 (0.65-0.82)	0.097<0.001<0.0010.006<0.001	1.17 (1.09-1.27)0.74 (0.70-0.79)0.77 (0.69-0.85)1.03 (0.85-1.26)0.90 (0.81-1.00)	<0.001<0.001<0.0010.730.060
Median household income26th-50thvs 0th-25th51st-75thvs 0th-25th76th-100thvs 0th-25th	0.94 (0.90-0.99)0.94 (0.90-0.99)0.96 (0.91-1.01)	0.0160.0110.13	0.95 (0.90-0.99)0.89 (0.84-0.94)0.93 (0.88-0.99)	0.030<0.0010.019
Smoking	0.97 (0.93-1.00)	0.069	0.91 (0.88-0.95)	<0.001





Heart failure	1.20 (1.08-1.35)	0.001	0.83 (0.71-0.96)	0.013
Previous MI	1.04 (0.99-1.07)	0.107	1.10 (1.04-1.16)	0.001
Previous PCI	0.99 (0.95-1.04)	0.75	1.05 (1.00-1.10)	0.055
Previous CABG	1.09 (1.03-1.16)	0.005	1.09 (1.02-1.16)	0.013
Atrial fibrillation	1.30 (1.24-1.36)	<0.001	1.56 (1.49-1.64)	<0.001
Previous stroke/TIA	1.17 (1.11-1.24)	<0.001	1.14 (1.07-1.21)	<0.001
Peripheral vascular disease	1.20 (1.14-1.25)	<0.001	1.13 (1.07-1.20)	<0.001
Chronic lung disease	1.45 (1.39-1.51)	<0.001	1.23 (1.17-1.29)	<0.001
Chronic renal failure	1.44 (1.38-1.50)	<0.001	1.58 (1.49-1.66)	<0.001
Liver disease	1.58 (1.42-1.75)	<0.001	1.20 (1.04-1.39)	0.013





Urban location	1.27 (0.88-1.84)	0.20	1.72 (1.15-2.57)	0.008
FFR	1.16 (1.05-1.28)	0.003	1.15 (1.03-1.27)	0.010
Drug eluting stent	0.81 (0.78-0.84)	<0.001	0.84 (0.80-0.87)	<0.001
Complete heart block	0.93 (0.80-1.09)	0.36	1.16 (1.00-1.35)	0.047
Stroke/TIA	0.95 (0.87-1.05)	0.33	0.86 (0.78-0.96)	0.005
Cardiogenic shock	0.91 (0.83-1.01)	0.082	1.13 (1.01-1.27)	0.033
Vascular complication	1.24 (1.06-1.45)	0.009	0.96 (0.77-1.19)	0.71
Emergency CABG	0.90 (0.77-1.05)	0.20	0.79 (0.67-0.93)	0.006
Length of stay (per 1 day increment)	0.98 (0.97-0.98)	<0.001	0.98 (0.97-0.98)	<0.001




Supplementary Table 1: Classification of CCS codes for Readmissions Causes
Causes of readmission	CCS code	Diagnosis
Respiratory	127	Chronic obstructive pulmonary disease and bronchietasis
	128	Asthma
	130	Pleurisy, pneumothorax, pulmonary collapse
	131	Respiratory failure, insufficiency and arrest
	132	Lung disease due to external agents
	133	Other lower respiratory disease













	78	Other CNS infection and poliomyelitis
	90	Inflammation or infection of eye
	122	Pneumonia
	123	Influenza
	124	Acute and chronic tonsillitis
	125	Acute bronchitis
	126	Other upper respiratory infections
	129	Aspiration pneumonitis
	135	Intestinal infection
	197	Skin and subcutaneous tissue infections
	201	Infective arthritis and osteomyelitis (except that caused by tuberculosis or sexually transmitted disease)
Bleeding 	60	Acute posthemorrhagic anemia
	153	Gastrointestinal hemorrhage
	182	Hemorrhage during pregnancy; abrutio placenta; placenta previa
Peripheral vascular disease 	114	Peripheral and visceral atherosclerosis
	115	Aortic, peripheral and visceral artery aneurysms
	116	Aortic and peripheral arterial embolism or thrombosis
	117	Other circulatory disease
	118	Phlebitis, thrombophlebitis and thromboembolism
	119	Varicose veins of lower extremities
Genitourinary 	159	Urinary tract infection
	160	Calculus of the urinary tract
	161	Other diseases of kidney and ureters
	162	Other diseases of bladder and urethra
	163	Genitourinary symptoms and ill-defined conditions
	164	Hyperplasia of prostate
	165	Inflammatory conditions of the male genital organs
	166	Other male genital disorders
	170	Prolapse of female genital organs
	175	Other female genital disorders
	215	Genitourinary congenital anomalies
Renal disease	156	Nephritis; nephrosis; renal sclerosis
	157	Acute and unspecified renal failure
	158	Chronic kidney disease
Gastrointestinal 	138	Esophageal disorders
	139	Gastroduodenal ulcer (except hemorrhage)
	140	Gastritis and duodenitis
	141	Other disorders of stomach and duodenum
	142	Appendicitis and other appendiceal conditions
	143	Abdominal hernia
	144	Regional enteritis and ulcerative colitis
	145	Intestinal obstruction without hernia
	146	Diverticulosis and diverticulitis
	147	Anal and rectal conditions












	110	Occlusion of stenosis of precerebral arteries
	111	Other and ill-defined cerebrovascular disease
	112	Transient cerebral ischemia
	113	Late effects of cerebrovascular disease
Trauma	207	Pathological fracture
	225	Joint disorders and dislocations; trauma-related
	226	Fracture of neck of femur (hip)
	227	Spinal cord injury
	228	Skull and face fractures
	229	Fracture of upper limb




	234	Crushing injury or internal injury
	235	Open wounds of head; neck; and trunk
	236	Open wounds of extremities
	239	Superficial injury; contusion
	244	Other injuries and conditions due to external causes
	260	All (external causes of injury and poisoning)
Endocrine/metabolic	48	Thyroid disorders
	49	Diabetes mellitus without complication
	50	Diabetes mellitus with complication
	51	Other endocrine disorders
	53	Disorders of lipid metabolism
	58	Other nutritional and endocrine/metabolic disorders
	186	Diabetes or abnormal glucose tolerance complicating pregnancy; childbirth; or the puerperium
Neuropsychiatric 	650	Adjustment disorders
	651	Anxiety disorders
	652	Attention-deficit, conduct, and disruptive behavior disorders
	653	Delirium, dementia, and amnestic and other cognitive disorders
	654	Developmental disorders
	655	Disorders usually diagnosed in infancy and childhood or adolescence
	656	Impulse control disorders, NEC
	657	Mood disorders
	658	Personality disorders
	659	Schizophrenia and other psychotic disorders
	660	Alcohol-related disorders
	661	Substance-related disorders
	662	Suicide and intentional self-inflicted injury
	663	Screening and history of mental health and substance abuse codes
	670	Miscellaneous mental health disorders
	79	Parkinson's disease
	80	Multiple sclerosis




	85	Coma, stupor and brain damage
	95	Other nervous system disorders
	216	Nervous system congenital anomalies
	650	Adjustment disorders
	651	Anxiety disorders
	652	Attention-deficit, conduct, and disruptive behavior disorders
	653	Delirium, dementia, and amnestic and other cognitive disorders
	654	Developmental disorders
	655	Disorders usually diagnosed in infancy and childhood or adolescence
	656	Impulse control disorders, NEC
	657	Mood disorders
	658	Personality disorders
	659	Schizophrenia and other psychotic disorders
	660	Alcohol-related disorders
	661	Substance-related disorders
	662	Suicide and intentional self-inflicted injury
	663	Screening and history of mental health and substance abuse codes
	670	Miscellaneous mental health disorders




	15	Cancer of rectum and anus
	16	Cancer of liver and intrahepatic bile ducts
	17	Cancer of pancreas
	18	Cancer of other GI organs, peritoneum
	19	Cancer of bronchus, lung
	20	Cancer of other respiratory and intrathoracic
	21	Cancer of bone and connective tissue
	22	Melanoma of skin





	28	Cancer of other female genital organs
	29	Cancer of prostate
	30	Cancer of testis
	31	Cancer of other male genital organs
	32	Cancer of bladder
	33	Cancer of kidney and renal pelvis
	34	Cancer of other urinary organs






	41	Cancer, other and unspecified primary
	42	Secondary malignancies
	43	Malignant neoplasm without specification of site
	44	Neoplasm of unspecified nature or uncertain behaviour
	46	Benign neoplasm of uterus
	47	Other and unspecified benign neoplasm
	59	Deficiency and other anemias
	61	 Sickle cell anemia
	62	Coagulation and hemorrhagic disorders
	63	Disease of white blood cells
	64	Other hematologic conditions
Rheumatology problem	54	Gout and other crystal arthropathies
Opthalmology problem	86	Cataract
	87	Retinal detachment defects, vascular occlusion and retinopathy
	88	Glaucoma
	89	Blindness and vision defects
	91	Other eye disorders
ENT problem	92	Otitis media and related conditions
	93	Conditions associate with dizziness or vertigo
	94	Other ear and sense organ disorder
Non-specific chest pain	102	Non-specific chest pain
Oral health problem	136	Disorders of teeth and jaw
	137	Diseases of mouth; excluding dental
Obstetric admission including pregnancy	174	Female infertility





	181	Other complications of pregnancy





	190	Fetal distress and abnormal forces of labor
	191	Polyhydramnios and other problems of amniotic cavity
	192	Umbilical cord complication
	193	OB-related trauma to perineum and vulva
	194	Forceps delivery
	195	Other complications of birth; puerperium affecting management of mother
	196	Other pregnancy and deliver including normal
	218	Liveborn
	219	Short gestation; low birth weight; and fetal growth retardation
	220	Intrauterine hypoxia and birth asphyxia
	223	Birth trauma
	224	Other perinatal conditions
Dermatology problem	198	Other inflammatory condition of skin
	199	Chronic ulcer of skin
	200	Other skin disorders
Poisoning	241	Poisoning by psychotrophic agents
	242	Poisoning by other medication and drugs
	243	Poisoning by nonmedical substances
Syncope	245	Syncope
Other non-cardiac 	10	Immunization and screening for infectious disease
	45	Maintenance chemotherapy, radiotherapy
	52	Nutritional deficiencies




	121	Other diseases of veins and lymphatics
	167	Nonmalignant breast conditions




	202	Rheumatoid arthritis and related disease
	203	Osteoarthritis
	204	Other non-traumatic joint disorders




	210	Systemic lupus erythematosus and connective tissue disorders
	211	Other connective tissue disease
	212	Other bone disease and musculoskeletal deformities
	217	Other congenital anomalies
	237	Complication of device; implant or graft
	238	Complications of surgical procedure or medical care
	240	Burns









	258	Other screening for suspected conditions (not mental disorders or infectious disease)
	259	Residual codes; unclassified
Heart failure 	108	Congestive heart failure non-hypertensive
Arrhythmia 	106	Cardiac dysrrhythmias
	107	Cardiac arrest and ventricular fibrillation
Conduction disorder 	105	Conduction disorders
Valve disorders 	96	Heart valve disorder
Hyper/hypotension 	98	Essential hypertension
	99	Hypertension with complications and secondary hypertension
	183	Hypertension complicating pregnancy; childbirth and the puerperium
	249	Shock
Pericarditis 	97	Peri-, endo- and myocarditis, cardiomyopathy
Coronary artery disease including angina 	101	Coronary atherosclerosis and other heart disease 
Acute myocardial infarction  	100	Acute myocardial infarction
Others (cardiac)  	103	Pulmonary heart disease
	104	Other and ill-defined heart disease
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